Evotec stock trades close to 52-week low as EBITDA turns negative
Published on 08/21/2026 at 07:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec (DE0005664809) stock is struggling in August 2026 as the German biotech company reported a double-digit revenue decline and a significantly wider adjusted EBITDA loss for the first half of 2026, alongside a cautious full-year outlook confirmed in mid-August.
Half-year 2026 results show revenue decline
According to a detailed earnings overview published on August 21, 2026, Evotec generated revenue of EUR300.1 million in the first half of 2026, representing a 19.2 percent decline compared to the same period of the previous year. The earnings overview notes that this contraction reflects weaker demand in parts of the companys discovery and development pipeline.
The same overview highlights that Evotecs adjusted EBITDA for the first half of 2026 fell to a loss of EUR42.7 million, compared with a loss of EUR1.9 million in the first half of the prior year. This means the adjusted EBITDA loss widened by EUR40.8 million year over year in the latest reporting period.
Evotecs management also confirmed a lowered full-year 2026 outlook that had already been communicated in July 2026. For the full year 2026, the company now expects revenue between EUR570 million and EUR610 million and an adjusted EBITDA in a range from negative EUR70 million to negative EUR105 million, highlighting that profitability will stay under pressure despite ongoing cost measures.
Stock trades close to its 52-week low
The same August 21, 2026 market commentary indicates that Evotec shares closed a recent trading session at EUR3.39, only a few percent above the 52-week low of EUR3.19 reached earlier in 2026. The commentary emphasizes that this price level leaves the stock down 38 percent since the beginning of 2026 and 45 percent over the past twelve months, underscoring how investors have reacted to the deteriorating earnings profile.
The same source notes that Evotec shares are trading at a pronounced discount to their long-term trend. At EUR3.39, the stock stands 33 percent below its 200-day moving average of EUR5.06, indicating a persistent downtrend that has not yet been broken by the markets despite the companys updated guidance.
Another trading report from August 20, 2026 shows that Evotec shares on the XETRA platform fell intraday to EUR3.34, a decline of 1.8 percent versus the previous close at that time, reinforcing that the stock remains volatile at low levels. The XETRA trading update notes that Evotec was among the weaker names in its index that afternoon as investors continued to digest the latest half-year results.
Guidance and investor implications
With revenue in the first half of 2026 at EUR300.1 million and full-year guidance of EUR570 million to EUR610 million, Evotecs implied second-half revenue range stands between EUR269.9 million and EUR309.9 million, suggesting that management expects at least some stabilization or modest growth in the remainder of the year versus the first six months.
However, the midpoint of the adjusted EBITDA guidance at negative EUR87.5 million, compared with the reported first-half adjusted EBITDA loss of EUR42.7 million, indicates that losses could deepen in the second half of 2026 if the company does not execute on cost controls or if revenue remains under pressure. For investors, this raises questions about how quickly Evotec can return to positive operating profitability.
The pronounced share price decline of 38 percent since the start of 2026, combined with the 45 percent drop over the past twelve months, means that expectations embedded in Evotecs valuation have already reset significantly. At the same time, the current stock price only marginally above the 52-week low of EUR3.19 and well below the 200-day moving average of EUR5.06 signals that the market is still assigning a considerable risk discount to the companys earnings outlook.
Evotecs business model and collaborations
Evotec operates as a drug discovery and development partner for pharmaceutical and biotechnology companies, leveraging its platforms in areas such as small molecules, biologics, and precision medicine. The company generates revenue from research collaborations, milestones, and, in some cases, royalties on successfully commercialized therapies.
The half-year 2026 figures suggest that some collaboration revenues have softened, contributing to the 19.2 percent year-over-year decline in first-half revenue to EUR300.1 million. This development underscores how sensitive Evotecs top line can be to project timing and partner decisions, especially when larger programs reach critical milestones earlier than expected or are delayed.
Despite the current setback in revenue and profitability, the companys guidance for full-year revenue between EUR570 million and EUR610 million implies that management still sees a broad opportunity set in its pipeline and partnership network. Investors will watch closely whether new or expanded collaborations can offset current headwinds and support a gradual improvement in margins beyond 2026.
Stock performance and trading venue
Evotec shares are primarily listed on the XETRA platform in Germany, with trading in euros. The reported closing price of EUR3.39 in August 2026 and the intraday quote of EUR3.34 on August 20, 2026 underline that the stock is currently trading in a narrow range close to its 52-week low, suggesting that market participants remain cautious pending further evidence of a turnaround in earnings.
For investors, key upcoming catalysts will likely include the companys next quarterly update, any revisions to guidance, and potential announcements on new strategic partnerships. The balance between short-term earnings pressure and long-term pipeline potential will play a central role in determining whether Evotec stock can stage a sustained recovery from current levels.
Representative Evotec collaboration
Evotecs business is built around multi-year discovery alliances with major pharmaceutical and biotechnology companies, where it provides research capabilities and platform technologies across early-stage projects. These collaborations are typically structured with upfront research payments, development milestones, and potential downstream royalties, aligning Evotecs interests with its partners long-term success.
Such a partnership-based model means that Evotecs revenue and adjusted EBITDA can fluctuate significantly from period to period, depending on the timing of milestone events and the progression of specific programs. The first-half 2026 revenue decline and the wider adjusted EBITDA loss to negative EUR42.7 million highlight how changes in project mix can impact reported financials, even when the broader pipeline remains active.
Evotec stock and recent price level
Evotec stock, listed on XETRA, last highlighted in recent market commentary at EUR3.39, reflects investors cautious stance following the companys first-half 2026 results and updated full-year guidance. This price, only slightly above the 52-week low of EUR3.19 and 33 percent below the 200-day moving average of EUR5.06, indicates that the stock remains under significant pressure as of late August 2026.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVT
Exchange: XETRA
Sector / Industry: Biotechnology
